Skip to main content
SpringerLink
Log in

Survival and Recurrence After Breast Cancer in BRCA1/2 Mutation Carriers

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: Genetic mutation is responsible for approximately 10% of breast cancers. The purpose of this study was to compare breast cancer survival and recurrence rates between BRCA1/2 mutation carriers and noncarriers.

Methods: Using the Columbia Presbyterian breast cancer database, we collected the tissue blocks of all patients younger than 65 years of age and of Jewish descent. The patients were contacted and the data updated. DNA was extracted from the tissue blocks and tested for the common mutations. The results of the genetic mutation and updated database were anonymized and merged. The survival and recurrence rates were compared between mutation carriers and noncarriers.

Results: A total of 739 breast cancer cases in 715 patients were identified. We were able to test 487 patients. We identified 30 BRCA1 and 21 BRCA2 mutation carriers, for an incidence of 10.36%. The median follow-up for the patients tested was 50 months. BRCA1 patients more frequently had estrogen- and progesterone-negative tumors and had a higher incidence of positive nodes. BRCA1 patients received chemotherapy more frequently. The incidence of in situ disease was similar for mutation and non–mutation carriers. BRCA1/2 mutation carriers had a higher incidence of bilateral disease. There was no difference in 5- or 10-year overall and breast cancer–specific survival between mutation and non–mutation carriers.

Conclusions: Breast cancer patients with BRCA1/2 mutations have a similar outcome as non–mutation carriers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Newman B, Mu H, Butler ML, et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998;279:915–921.

    Article  PubMed  CAS  Google Scholar 

  2. Malone KE, Daling JR, Neal C, et al. Frequency of BRCA1/BRCA2 mutations in a population based sample of young breast carcinoma cases. Cancer 2000;88:1393–1402.

    Article  PubMed  CAS  Google Scholar 

  3. Fodor F, Weston A, Bleiweiss I, et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 1998;63:45–51.

    Article  PubMed  CAS  Google Scholar 

  4. Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999;91:1241–1247.

    Article  PubMed  CAS  Google Scholar 

  5. Robson M, Rajan P, Rosen PP, et al. BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res 1998;58:1839–1842.

    PubMed  CAS  Google Scholar 

  6. Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996;77:697–709.

    Article  PubMed  CAS  Google Scholar 

  7. Porter DE, Dixon M, Smyth E, Steel CM. Breast cancer survival in BRCA1 carriers. Lancet 1993;341:184–185.

    Article  PubMed  CAS  Google Scholar 

  8. Porter DE, Cohen BB, Wallace MR, et al. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 germline mutation in families linked to BRCA1 on chromosome 17q12–21. Br J Surg 1994;81:1512–1515.

    Article  PubMed  CAS  Google Scholar 

  9. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351:316–321.

    Article  PubMed  CAS  Google Scholar 

  10. Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998;16:397–404.

    PubMed  CAS  Google Scholar 

  11. Robson M, Gilewski T, Haas B, et al. BRCA-associated breast cancer in young women. J Clin Oncol 1998;16:1642–1649.

    PubMed  CAS  Google Scholar 

  12. Ansquer Y, Gautier C, Fourquet A, Asselain B, Stoppa-Lyonnet D. Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group. Lancet 1998;352:541.

    Article  PubMed  CAS  Google Scholar 

  13. Robson M, Levin D, Federici M, et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA founder mutations. J Natl Cancer Inst 1999;91:2112–2117.

    Article  PubMed  CAS  Google Scholar 

  14. Foulkes WD, Wong N, Brunet JS, et al. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 1997;3:2465–2469.

    PubMed  CAS  Google Scholar 

  15. Foulkes WD, Chappuis PO, Wong N, et al. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 2000;11:307–313.

    Article  PubMed  CAS  Google Scholar 

  16. Karp SE, Tonin PN, Begin LR, et al. Influence of BRCA1 mutations on nuclear grade and receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 1997;80:435–441.

    Article  PubMed  CAS  Google Scholar 

  17. Armes JE, Trute L, White D, et al. Distinct molecular pathogenesis of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population based study. Cancer Res 1999;59:2011–2017.

    PubMed  CAS  Google Scholar 

  18. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 and BRCA2 mutations and sporadic cases. Lancet 1997;349:1505–10.

    Article  Google Scholar 

  19. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90:1138–1145.

    Article  PubMed  CAS  Google Scholar 

  20. Armes JE, Venter DJ. The pathology of inherited breast cancer. Pathology 2002;34:309–314.

    Article  PubMed  Google Scholar 

  21. Lakhani SR, van de Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310–2318.

    Article  PubMed  CAS  Google Scholar 

  22. Levine DA, Federici MG, Reuter VE, Boyd J. Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer. Gynecol Oncol 2002;85:431–434.

    Article  PubMed  CAS  Google Scholar 

  23. Jazaeri AA, Yee CJ, Sotiriou C, et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. Natl Cancer Inst 2002;94:990–1000.

    CAS  Google Scholar 

  24. Eisinger F, Stoppa-Lyonnet D, Londy M, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996;56:471–474.

    PubMed  CAS  Google Scholar 

  25. Pierce LJ, Strawderman M, Narod SA, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 2000;18:3360–3369.

    PubMed  CAS  Google Scholar 

  26. Haffty BG, Harrold E, Khan AJ, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 2002;359:1471–1477.

    Article  PubMed  Google Scholar 

  27. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1–15.

    Google Scholar 

  28. Hoogerbrugge N, Bult P, de Widt-Levert JM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 2003;21:41–45.

    Article  PubMed  CAS  Google Scholar 

  29. Ren Q, Carbonne C, Potoczek M, et al. Differential response to BRCA1 wild type and BRCA1 mutant breast cancer cells to ionizing radiation and paclitaxel (abstract). Clin Cancer Res 2001; 7(Suppl):3723s.

    Google Scholar 

  30. Fan S, Yuan R, Ma YX, et al. Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1. Oncogene 2001;20:8215–8235.

    Article  PubMed  CAS  Google Scholar 

  31. Bhattacharyya A, Ear US, Koller BH, et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275:23899–23903.

    Article  PubMed  CAS  Google Scholar 

  32. Husain A, He G, Venkatraman ES, et al. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998;58:1120–1123.

    PubMed  CAS  Google Scholar 

  33. Abbott DW, Freeman MI, Holt JT. Double-strand repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 1998;90:978–985.

    Article  PubMed  CAS  Google Scholar 

  34. Freneaux P, Stoppa-Lyonnet D, Mouret E, et al. Low expression of bcl-2 in BRCA1-associated cancers. Br J Cancer 2000;83:1318–1322.

    Article  PubMed  CAS  Google Scholar 

  35. Chappuis PO, Goffin J, Wong N, et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002;39:608–610.

    Article  PubMed  CAS  Google Scholar 

  36. Goffin JR, Chappuis PO, Begin LR, et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma. Cancer 2003;97:527–536.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Breast Surgery, Columbia-Presbyterian Comprehensive Breast Center, New York, New York

    Mahmoud El-Tamer MD, Donna Russo MS, Beth-Ann Ditkoff MD & Freya Schnabel MD

  2. Departments of Pathology, Columbia-Presbyterian Comprehensive Breast Center, New York, New York

    Lourdes P. Bernardino MD, Robert Mazziotta MD & Mahesh Mansukhani MD

  3. Departments of Biostatistics, Columbia-Presbyterian Comprehensive Breast Center, New York, New York

    Andrea Troxel DSc

  4. Departments of Clinical Surgery, Columbia-Presbyterian Comprehensive Breast Center, New York, New York

    Alison Estabrook MD

  5. Columbia-Presbyterian Hospital-Breast Center, Atchley Pavilion, 10th Floor, 161 Fort Washington Ave, New York, NY, 10032

    Mahmoud El-Tamer MD

Authors
  1. Mahmoud El-Tamer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donna Russo MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Troxel DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lourdes P. Bernardino MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert Mazziotta MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alison Estabrook MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Beth-Ann Ditkoff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Freya Schnabel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mahesh Mansukhani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mahmoud El-Tamer MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

El-Tamer, M., Russo, D., Troxel, A. et al. Survival and Recurrence After Breast Cancer in BRCA1/2 Mutation Carriers. Ann Surg Oncol 11, 157–164 (2004). https://doi.org/10.1245/ASO.2004.05.018

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2004.05.018

Key Words

Search

Navigation